Department of Neuroscience, Clinical Neurophysiology, Uppsala University, Uppsala, Sweden.
Department of Neurology, Nottingham University, Hospitals NHS Trust, Queens Medical Centre, Nottingham, Nottinghamshire, UK.
J Neuroimmunol. 2018 Aug 15;321:164-170. doi: 10.1016/j.jneuroim.2018.05.003. Epub 2018 May 8.
There are no biomarkers for late onset myasthenia gravis (LOMG; onset >50 years). We evaluated circulating microRNA in a discovery cohort of 4 LOMG patients and 4 healthy controls and in a prospective diagnostic validation cohort of 73 LOMG patients (48 male) with longitudinal follow-up samples. In immunosuppression naïve patients, levels of miRNAs miR-150-5p, miR-21-5p and miR-30e-5p decreased in parallel with clinical improvement after initiation of immunosuppression and their levels positively correlated with the clinical MG composite score. Levels of miR-150-5p and miR-21-5p were lower in patients with ocular compared to generalized LOMG. Circulating miR-150-5p, miR-21-5p and miR-30e-5p correlate with the clinical course in LOMG.
尚无迟发性重症肌无力 (LOMG; 发病年龄 >50 岁) 的生物标志物。我们在一个包含 4 名 LOMG 患者和 4 名健康对照的发现队列中评估了循环 microRNA，并在一个包含 73 名 LOMG 患者（48 名男性）的前瞻性诊断验证队列中进行了纵向随访样本评估。在免疫抑制初治患者中，miR-150-5p、miR-21-5p 和 miR-30e-5p 的水平在开始免疫抑制后与临床改善平行下降，其水平与临床 MG 综合评分呈正相关。与全身性 LOMG 相比，眼部 LOMG 患者的 miR-150-5p 和 miR-21-5p 水平较低。循环 miR-150-5p、miR-21-5p 和 miR-30e-5p 与 LOMG 的临床病程相关。
